SIRION signs license and collaboration agreement with Sanofi to develop improved tissue-selective AAV vectors to realize effective gene therapy treatments for disorders affecting major human organs. https://t.co/PQcpK9GKuq
Very excited to release the beta version of our Outcomes4me app designed to empower breast cancer patients. Personalized NCCN guidelines-based treatment plan and precise trial matching. Get EARLY ACCESS to the app and help us shape this product:
https://t.co/BUj21QKMxE
Meet Brian. This is his story. He is an ALS patient. He is alive. He is fighting. He is determined to find a cure.
Join him today: https://t.co/01Uu5kLelK
And please RT. Thank you for daring to be awesome.
At 37, with two little kids, I was told I had ALS. No cure. 6 months to live.
That’s not how my story will end. I will see them get married. You and me, we’re going to rewrite the ALS story.
How?
1. Follow @iamalsorg
2. Retweet this post
Thank you for being great today.
There is no hope until there is. Today, I AM ALS launches. Today, we have more hope that a cure will be found. Together, we can. Join us: https://t.co/01Uu5ktCXa
It started when he couldn’t grasp a pen. Diagnosed with ALS at 37, former Obama staffer hopes to use campaign skills to raise funds for a cure. - Chicago Tribune https://t.co/LFljAFb7A5
“I think guys would be willing to take 10, 20 years off the end of their lives, in order to get out there on Sunday and play.” 22 years later, now diagnosed with ALS, former Atlanta Falcon Tim Green stands by that statement. Green tells his story, Sunday. https://t.co/dS77vHCXNA
Honored to team w/Tim to #TackleALS. Tune in Sun to hear Tim’s story, why Dr. Cudkowicz, Chief of Neurology & Director, Healey Center for ALS @ MGH, believes that w/proper funding & partnerships, therapy development will be accelerated for people w ALS living all over the world.
Researchers have discovered tiny channels through the skull’s inner layer that carry inflammatory cells from marrow directly to the brain https://t.co/APdEoqMWd3
Did you miss today's #ALS webinar? Dr. Richard Bedlack @dukealsclinic reviewed the interesting background science on curcumin and outlined a new patient-centric clinical trial of a particular form of it that will occur at Duke University in 2019. https://t.co/v5TuvbcKLJ